Legend Biotech’s Q1 2026 EPS of -$0.15 fell short of the $0.01 forecast. Revenue reached $305.1 million, slightly below expectations. The stock surged 12.08% pre-market despite the earnings miss.

Good morning, everybody. We're waiting for the few final people to pop into the conference, and we'll get started in just a few seconds. Everybody has joined the conference. So Randy, good to go.

Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech Reports Third Quarter 2024 Financial Results. At this time, all participants are in a listen-only mode. After the speakers' ...

Gross margins improved dramatically from 21% to 41% year-over-year. Operating expenses were reduced by 35% compared to the previous year. Revenue grew by 4.2% quarter-over-quarter, reaching CAD ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Operator: Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech Reports Third Quarter 2024 Financial Results. At this time, all participants are in a listen-only mode. After the ...

Earnings call Legend Power Systems delivered flat revenue of CAD 545,000 in Q2 2026, with gross margin doubling YoY to 41% due to cost reductions. Management highlighted a significant order intake in ...

Legend Power Systems reported its fiscal Q2 2026 earnings, showcasing a modest revenue increase and a significant improvement in gross margins. The company highlighted its strategic focus on cost ...

Legend Biotech (LEGN) is scheduled to announce Q3 earnings results on Tuesday, November 11th, before market open. The consensus EPS Estimate is -$0.12 (+64.7% Y/Y) and the consensus Revenue Estimate ...